Summary of minutes of EUCAST Steering Committee Meeting
Copenhagen, Denmark 28-29 April 2015

Attending
Dr Derek F.J. Brown  DB  Scientific Secretary  United Kingdom
Dr Rafael Cantón  RC  Chairperson  Spain
Prof Gerard Lina  GL  CA-SFM  France
Dr Christian Giske  CG  SRGA  Sweden
Prof Gunnar Kahlmeter  GK  Clinical Data Co-ordinator  Sweden
Dr P. Christoffer Lindemann  CL  NWGA  Norway
Prof Alasdair P. MacGowan  AM  BSAC  United Kingdom
Prof Johan W. Mouton  JM  CRG  The Netherlands
Prof Sören Gatermann  SG  EUCAST General Committee  Germany
Dr Iztok Štrumbelj  IS  EUCAST General Committee  Slovenia
Prof Jan Verhagen  JV  EUCAST General Committee  Belgium
Visiting GC members:
Prof Ron Jones  RJ  EUCAST General Committee  USA
Prof John Turnidge  JT  EUCAST General Committee  Australia
EMA representative
Dr Radu Botgros  RB  EMA, London  UK
Present for items on breakpoint issues and agents without breakpoints
Dr Erika Matuschek  EM  EUCAST Development Laboratory  Sweden
Present for item on ceftaroline  Astra Zeneca representatives
Present for item on plazomicin  Achaogen representatives
Present for item on lefamulin  Nabriva Therapeutics representatives

Chairman’s welcome

Minutes of meeting of 16-17 February 2015
The minutes were accepted as a correct record.

Matters arising from minutes of 16-17 February 2015 (items not covered by agenda)
None.

New agents
Tedizolid, dalbavancin and oritavancin have been approved and EUCAST breakpoints published on the EUCAST website as an addendum to breakpoint tables v 5.0. Ceftolozane-tazobactam breakpoint discussions were continued.

Confidentiality issues regarding new agents were emphasised and the Information for Industry section on the EUCAST website has been amended to clarify the situation.

EUCAST rationale documents
The ceftobiprole document is to be completed and the ampicillin, amoxicillin-clavulanic acid and trimethoprim-sulfamethoxazole documents are to be released.

Subcommittees
Antifungal susceptibility testing (AFST): Changes to the Steering Committee were approved and will be detailed on the EUCAST website.

Whole genome sequencing (WGS): Professor Neil Woodford (London, UK) will chair this new subcommittee and the final remit and the proposed members are being considered.

VetCAST: Professor Dik Mevius will chair this new subcommittee. The structure of the subcommittee will be similar to that of the AFST subcommittee, with a core group of four members.

ECOFFs: It was agreed to set up a subcommittee to define the process of setting ECOFFs.

Breakpoint issues
Susceptibility testing of H. influenzae against β-lactam agents: There are some problems when there are PBP changes. A disk diffusion screening test is being developed with the benzylpenicillin.

Definition of the intermediate category: Proposed new definitions excluding the concept of a buffer zone will
be released for consultation over the summer.

Breakpoint table comments when high dose therapy: A standard format for comments was agreed.
Breakpoint table comments when resistance is rare: The combinations where there are comments in breakpoint tables are being reviewed.

Susceptibility testing of *N. gonorrhoeae*: An MIC method will be recommended and no further development work on disk diffusion undertaken at present. A guidance document will be produced.

Colistin breakpoints: Discussions are continuing in the joint EUCAST-CLSI group.

Review of carbapenem breakpoints: Discussions are continuing.

Expert rules: A review of current rules is in progress.

Guidelines for manufacturers on data required for new antimycobacterial agents: The report on a EUCAST-ESGMYC workshop in 2014 will be released on the EUCAST website.

Daptomycin breakpoints for enterococci: A guidance note explaining the EUCAST IE designation will be released for wide consultation.

Tigecycline breakpoints for Enterobacteriaceae: A consultation document will be released on proposals to reduce breakpoints for Enterobacteriaceae.

Nitroxoline breakpoints: Proposed breakpoints will be released for consultation.

Spiramycin breakpoints: MIC distributions are needed.

Temocillin breakpoints: Breakpoints will be considered when results of current Monte Carlo simulation studies are completed.

Agents without breakpoints: A document indicating why EUCAST breakpoints are not available for some agents is being prepared.

Review of fluoroquinolone breakpoints: A consultation document on proposals for changes is being prepared.

*Aerococcus* spp.: EM presented preliminary work at the EUCAST Development Laboratory

**Organisms without EUCAST breakpoints**

*Aerococcus* spp.: Preliminary work on MIC-zone diameter correlations was reviewed.

*Kingella kingae*: Work on MIC distributions is planned.

A guidance note is being prepared on how laboratories should deal with isolates of organisms without breakpoints.

**EUCAST methods** No additional information.

**Implementation of EUCAST breakpoints** Uptake maps have been updated and were presented at ECCMID 2015.

**EUCAST websites** New sections giving website usage statistics and details of all open consultations and responses are being prepared. The subcommittee section has been updated.

**Publications and presentations**
The 2014 Garrod lecture “EUCAST - are we heading towards international agreement?” has been accepted for publication in JAC.

The EUCAST resistance mechanisms document will be reviewed.

**NACs** No additional information.
EUCAST SOPs SOP 3.0 is to be revised.

ESCMID ECCMID 2015 sessions were well attended and successful. Proposals for 2016 will be submitted. A proposal will be submitted for a EUCAST Postgraduate Educational Course to be held in Bochum, Germany in September 2016.

EMA A revised version of the EMA-EUCAST SOP is expected soon.

ECDC A new call for tender for EUCAST is yet to be released.

CLSI RC will attend the meeting in June 2015.

Ceftaroline AstraZeneca presented proposals for changes to current breakpoints.

Plazomicin Achaogen gave a preliminary presentation of the agent.

Lefamulin Nabriva gave a preliminary presentation of the agent.

Any other business None.

Next meetings
13-14 July 2015, Windsor, UK
7-8 September 2015, Malmö, Sweden
9-10 November, 2015, Dusseldorf, Germany
8-9 February 2016, Madrid, Spain
12-13 April 2016, Istanbul, Turkey

Ratified summary of minutes of meeting 28-29 April 2015. Prepared by DB, RC and GK